Vascular Inflammation Suppression to Treat Acute Coronary Syndrome for 16 Weeks - VISTA-16


Varespladib methyl is a novel nonspecific pan-secretory phospholipase A2 (sPLA2) inhibitor with favorable effects on atherosclerotic lesions in animal studies. It is considered to be a potent anti-inflammatory agent by interfering with arachidonic acid metabolism. The current trial sought to study the safety and efficacy of varespladib in patients with recent acute coronary syndrome (ACS) who were on atorvastatin.